Comparative Pharmacology
Head-to-head clinical analysis: CEFDINIR versus RESPORAL.
Head-to-head clinical analysis: CEFDINIR versus RESPORAL.
CEFDINIR vs RESPORAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefdinir is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting peptidoglycan cross-linking, leading to cell lysis and death.
RESPORAL contains theophylline, a methylxanthine that inhibits phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cAMP and cGMP levels. It also antagonizes adenosine receptors, resulting in bronchodilation and anti-inflammatory effects.
300 mg orally twice daily for 5-10 days, or 600 mg orally once daily for 10 days.
2 mg orally twice daily
None Documented
None Documented
Terminal elimination half-life: 1.7 ± 0.6 hours (range 1.4-2.3 h) in healthy adults; prolonged in renal impairment (e.g., up to 8 hours in end-stage renal disease).
Clinical Note
moderateCefdinir + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefdinir."
Clinical Note
moderateIron sucrose + Cefdinir
"The serum concentration of Cefdinir can be decreased when it is combined with Iron sucrose."
Clinical Note
moderateIron + Cefdinir
"The serum concentration of Cefdinir can be decreased when it is combined with Iron."
Clinical Note
moderateFerric pyrophosphate + Cefdinir
Terminal half-life is 12 hours (range 10-14 h), supporting twice-daily dosing in most patients.
Renal: 90-95% unchanged in urine via glomerular filtration and tubular secretion. Biliary/fecal: <1% biliary, <5% fecal.
Renal excretion accounts for 70% of elimination (30% unchanged), biliary/fecal 20%, and 10% metabolized.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic
"The serum concentration of Cefdinir can be decreased when it is combined with Ferric pyrophosphate."